- Investing Ideas
- Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
4
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
4 companies
AddLife
Market Cap: SEK 19.8b
Provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries.
ALIF B
SEK 162.40
7D
3.0%
1Y
-4.4%
Vitrolife
Market Cap: SEK 12.3b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 91.30
7D
3.3%
1Y
-34.1%
BioGaia
Market Cap: SEK 11.7b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 116.30
7D
1.0%
1Y
17.7%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%